Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation

Clinical Transplantation

Volumn 11, Issue 4, 1997, Pages 328-333

  McVicar, John P ^a,b   Kowdley, Kris ^a   Emond, Mary J ^a   Barr, Darlene ^a   Marsh, Christopher L ^a   Carithers Jr , Robert L ^a   Perkins, James D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti thymocyte globulin; Cyclosporine; Cytomegalovirus; Minnesota antilymphoblast globulin; Post transplant lymphoproliferative disease; United Network for Organ Sharing

Indexed keywords

ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; AZATHIOPRINE; BIOPSY; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUROMONAB-CD3; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0030758033     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. ASCHER NL, STOCK PG, BUMGARDNER GL, PAYNE WD, NAJARIAN JS. Infection and rejection of primary hepatic transplant in 93 consecutive patients treated with triple immunosuppressive therapy. Surg Gyn & Obst 1988: 167: 474.
2. KLINTMALM GB, NERY JR, HUSBERG BS, GONWA TA, TILLERY GW. Rejection in liver transplantation. Hepatology 1989: 10: 978.
3. VAN HOEK B, WEISNER RH, LUDWIG J, GORES GJ, MOORE, KROM RAF. Combination immunosuppression with azathioprine reduces the incidence of ductopenic rejection with vanishing bile duct syndrome after liver transplantation. Transpl Proc 1991: 23: 1403.
4. COSIMI AB, CHO SI, DELMONICO FL, KAPLAN MM, ROHRER RJ, JENKINS RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987: 43: 91.
5. NORMAN DJ, SHIELD CF, BARRY J, et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kid Dis 1988: 11: 107.
6. BRISTOW MR, GILBERT EM, O'CONNELL JB, et al. Non-renal transplant uses: OKT3 monoclonal antibody in heart transplantation. Am J Kid Dis 1988: 11: 135.
7. MILLIS JM, MCDIARMID SV, HIATT JR, et al. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 1989: 47: 82.
8. PIRSCH JD, KALAYOGLU M, HAFEZ GR, D'ALESSANDRO AM, SOLLINGER HW, BELZER FO. Evidence that the vanishing bile duct syndrome is vanishing. Transplantation 1990: 49: 1015.
9. COSIMI AB, JENKINS RL, ROHRER RJ, DELMONICO FL, HOFFMAN M, MONACO AP. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990: 125: 781.
10. PORTELA D, PATEL R, LARSON-KELLER JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995 171: 1014.
11. HADLEY S, SAMORE MH, LEWIS WD, JENKINS RL, KARCHMER AW, HAMMER SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995: 59: 851.
12. MCVICAR JP, KOWDLEY KV, BACCHI CE, et al. The natural history of untreated focal allograft rejection in liver transplant recipients. Liver Transpl and Surg 1996: 2: in 154.
13. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994: 344: 423.
14. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immuno-suppression in liver transplantation. N Engl J Med 1994: 331: 1110.
15. SOMMERAUER JF, ATKISON P, HOWARD J, GRANT D, WALL W. OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients. Transpl Proc 1994: 26: 154.
16. WALL WJ, GHENT CN, ROY A, MCALISTER VC, GRANT DR, ADAMS PC. Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation. Dig Dis Sci 1995: 40: 52.
17. DÉ P, BECHSTEIN WO, BLUMHARDT G, LANGE D, SCHATTENFROH N, NEUHAUS P. Early steroid-resistant rejection following orthotopic liver transplantation: New aspects of treatment with FK 506 instead of OKT3? Transpl Proc 1993: 24: 2693.
18. NEUHAUS P, BECHSTEIN WO, BLUMHARDT G, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993: 55: 1320.
19. MCDIARMID SV, BUSUTTIL RW, LEVY P, MILLIS MJ, TERASAKI PI, AMENT ME. The long-term outcome of OKT3 compared with cyclosporine prophylaxis after liver transplantation. Transplantation 1991: 52: 91.
20. WILLEMS F, ANDRIS F, ABRAMOWICZ D, et al. Induction of T-cell anergy by OKT3 requires cyclosporine insensitive activation signals. Transpl Proc 1995: 27: 1425.
21. SASAKI AW, LEE RG, PORAYKO MK, et al. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3. Transplantation 1993: 55: 216.
22. DAVIS CL, HARRISON KL, MCVICAR JP, FORG PJ, BRONNER MP, MARSH CL: Antiviral prophylaxis and the Epstein Barr virus related post transplant lymphoproliferative disorder. Clin Transpl 1995: 9: 53.